
Agilent Technologies company profile
$173.96+0.55%Close 13 Nov 2026 · Market value $48.72B · Next results 23 Nov 2026
About Agilent Technologies
Agilent Technologies, Inc. is a company that provides application-focused solutions for the laboratory workflow, including instruments, software, services and consumables. Its operations are organized into three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography and mass spectrometry instruments, cell analysis, pathology solutions, genomics, biomolecular analysis and specialty contract development and manufacturing services for oligonucleotide-based therapeutics. Agilent CrossLab provides services, consumables, software and laboratory automation. Applied Markets provides gas chromatography, spectroscopy, vacuum and other instruments. Customers include pharmaceutical and biopharmaceutical companies, diagnostics and clinical laboratories, academic and government institutions, and companies in chemicals, food, environmental and forensics markets. Products are sold primarily through direct sales, supplemented by distributors and resellers.
A summary of the business section of the company's latest annual report, filed 22 Dec 2025.
Company facts
| Ticker | A · NYSE |
|---|
| Sector | Instruments |
|---|
| Industry | Life Sciences Tools & Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 October |
|---|
| Reporting currency | USD |
|---|
| CIK | 1090872 |
|---|
| Latest annual report | 10-K, filed 22 Dec 2025 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Robert W. McMahon | Sr. VP and CFO | 117K · < 1% | Shares withheld for tax, 22 May 2025 |
|---|
| Koh Boon Hwee | Director | 61.6K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Padraig McDonnell | President and CEO · Director | 54.6K · < 1% | Shares withheld for tax, 3 Jun 2026 |
|---|
| George A. Scangos, PhD | Director | 38.5K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Daniel K. Podolsky, M.D. | Director | 36.0K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Rodney Gonsalves | V.P., Corporate Controller | 32.5K · < 1% | Shares withheld for tax, 21 Nov 2025 |
|---|
| Angelica Riemann | Senior Vice President | 30.5K · < 1% | Shares withheld for tax, 27 Feb 2026 |
|---|
| Sue H. Rataj | Director | 21.5K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Dow R. Wilson | Director | 18.2K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Mala Anand | Director | 14.5K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Otis Brawley, M.D. | Director | 10.8K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Simon May | Senior Vice President | 7.1K · < 1% | Shares withheld for tax, 8 May 2026 |
|---|
| Bret DiMarco | Senior Vice President | 5.1K · < 1% | Shares withheld for tax, 26 Nov 2025 |
|---|
| Mikael Dolsten, M.D., PhD | Director | 5.0K · < 1% | Open-market sale, 4 Sep 2026 |
|---|
| Judy Gawlik Brown | Director | 1.7K · < 1% | Grant or award, 19 Mar 2026 |
|---|
| Pascal Soriot | Director | 1.2K · < 1% | Shares withheld for tax, 19 Mar 2026 |
|---|
| Boehnlein Glenn S | Director | — | Grant or award, 8 Sep 2026 |
|---|
| KIRKWOOD JONAH PREVOST | Senior Vice President | — | Shares withheld for tax, 26 Jun 2026 |
|---|
| Buckner Michael Steven | Senior Vice President | — | Grant or award, 19 May 2026 |
|---|
| Henson Meghan | Senior Vice President | — | Shares withheld for tax, 31 Mar 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
A in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.